Clinical trials: Monoclonal Antibody
Anti MAG Neuropathy
This Study Aims to Investigate the Efficacy of Photobiomodulation in the Treatment of Anti-MAG-induced Peripheral Neuropathy (LASER-MAG)
Patients treated in the hematology department of the Quimper/Cornouaille Hospital Center for IgM monoclonal gammopathy with anti-MAG and symptomatic peripheral neuropathy often reach a therapeutic impasse.
- Trial name
- LASER-MAG (NCT07661667)
- Testing
- photobiomodulation
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Centre Hospitalier de Cornouaille
HIV
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
Background: In most people infected with human immunodeficiency virus (HIV), their immune system cannot control HIV infection. They need drugs called combination antiretroviral therapy (cART) to control the HIV.
- Trial name
- NCT02788175
- Testing
- Entyvio (Vedolizumab)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Head and Neck Cancer
Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer
The purpose of this study is to define the response and toxicities with the addition of Nimotuzumab to chemoradiation for head and neck cancer.
- Trial name
- NCT00702481
- Testing
- Nimotuzumab, Cisplatin, Radiation
- Where
- Singapore
- Volunteers
- 32 people
- Sponsor
- National Cancer Centre, Singapore
Hodgkin Lymphoma
A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma
The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL)
- Trial name
- NCT02572167
- Testing
- brentuximab vedotin, nivolumab
- Where
- 13 sites in United States
- Volunteers
- 93 people
- Sponsor
- Seagen Inc.
Covid19
A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19
The purpose of this research is to test whether a new medication called bamlanivimab is safe and effective at reducing the need for hospitalization due to COVID-19.
- Trial name
- B-EPIC (NCT04796402)
- Testing
- Bamlanivimab, Standard of Care
- Where
- Canada
- Volunteers
- 576 people
- Sponsor
- Fraser Health
Inhalational Anthrax
Intramuscular Dose-Escalation Study With ETI-204 in Adult Volunteers
This study is to evaluate the safety, local tolerability, pharmacokinetics (PK) and immunogenicity of escalating single intramuscular (IM) doses of ETI-204 in healthy volunteers
- Trial name
- NCT01932437
- Testing
- ETI-204
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Elusys Therapeutics
Healthy Participants Study
Accessorized Pre-Filled Syringe to Autoinjector Pharmacokinetic Bridging Study in Anifrolumab
This study will be conducted to compare the pharmacokinetic (PK) exposure after a single SC dose of anifrolumab administered using an AI with the PK exposure after a single subcutaneous (SC) dose of anifrolumab administered using…
- Trial name
- NCT05339100
- Testing
- Anifrolumab, Autoinjector, Accessorized Pre-Filled Syringe
- Where
- 3 sites in United States, Germany and 1 more
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Cold Agglutinin Disease
Therapy for Chronic Cold Agglutinin Disease
Chronic cold agglutinin disease (CAD) is a type of autoimmune hemolytic anemia (anemia due to destruction of red blood cells by abnormal antibodies).
- Trial name
- NCT00373594
- Testing
- Rituximab, Fludarabine
- Where
- 6 sites in Norway, Russia
- Volunteers
- 30 people
- Sponsor
- University of Bergen
Head and Neck Squamous Cell Carcinomas
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
The trial is being conducted to evaluate the efficacy and safety of Tislelizumab in combination with dasatinib and quercetin(combining immunotherapy and senolytics, COIS) in patients with head and neck squamous cell carcinoma who…
- Trial name
- NCT05724329
- Testing
- Tislelizumab + Dasatinib + Quercetin (neoadjuvant), surgery, Tislelizumab + Dasatinib + Quercetin (adjuvant)
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Glioblastoma
89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme
The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.
- Trial name
- NCT02410577
- Testing
- 89Zr-J591, PET/CT Scan, MRI
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer
The aim of this study is to determine the efficacy of combining the histone deacetylase (HDAC) inhibitor sodium valproate (VPA) with anti-EGFR monoclonal antibody (panitumumab or cetuximab) maintenance in the first-line treatment…
- Trial name
- NCT05694936
- Testing
- Sodium Valproate, Panitumumab, Cetuximab
- Where
- 12 sites in Australia
- Volunteers
- 38 people
- Sponsor
- Australasian Gastro-Intestinal Trials Group
Advanced Cancer
A Study Explore JS001+JS002 in Patients With Advanced Cancer
This open-label phase I clinical study with clinical development phase will evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JS002 combined with Toripalimab in advanced cancer patients, who has…
- Trial name
- NCT05128539
- Testing
- JS001(Toripalimab)+JS002
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumors
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1).
- Trial name
- NCT03379259
- Testing
- BGB-A333, BGB-A317
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 39 people
- Sponsor
- BeiGene
Inherited Metabolic Storage Diseases
Monoclonal Antibody Conditioning for Allogeneic Stem Cell Transplantation of Patients With Inherited Metabolic Storage Diseases
This study treats patients with an inherited disease that prevents the body from making a specific protein or enzyme needed for the body's metabolism.
- Trial name
- NCT00056979
- Testing
- CAMPATH-1H, Anti-CD45, FK506
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baylor College of Medicine
Parkinson Disease
Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology
This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology.
- Trial name
- NCT07544953
- Testing
- Lecanemab, Lecanemab non-administration group
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Yonsei University
Healthy
Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults
The purpose of this study is to test the safety and tolerability of HFB30132A when it is given by intravenously to healthy participants.
- Trial name
- NCT04590430
- Testing
- HFB30132A
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- HiFiBiO Therapeutics
Melanoma, Renal Carcinoma
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
An open-label, dose-escalation, phase I clinical study to evaluate the safety and tolerability of JS004 injection in the patients with advanced solid tumors who have failure in standard of care and are unable to tolerate standard…
- Conditions
- Melanoma, Renal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04773951
- Testing
- JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
- Where
- 11 sites in China
- Volunteers
- 47 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Osteoarthritis, Arthritis
Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With Osteoarthritis Of The Knee Or Hip
The purpose of this study is to investigate the long-term analgesic efficacy and safety of tanezumab for patients with osteoarthritis (OA) of the knee or hip currently experiencing partial benefit from, and are tolerating…
- Trial name
- NCT00809354
- Testing
- NSAID, tanezumab
- Where
- 333 sites in United States, Canada and 10 more
- Volunteers
- 2,720 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior…
- Trial name
- NCT00049751
- Testing
- Adalimumab
- Where
- 54 sites in United States
- Volunteers
- 3,000 people
- Sponsor
- Abbott
COVID-19, SARS CoV 2 Infection
Neutralizing Power of Anti-SARS-CoV-2 (Anti-COVID-19) Serum Antibodies
Natural infection, vaccines and treatments (like monoclonal antibodies) lead to the appearance of a neutralizing power in the serum (due to induced or injected antibodies).
- Trial name
- PNAS (NCT05315583)
- Testing
- Collection of biological samples
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Régional d'Orléans
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.